Without these hubs, the body’s anti-cancer immune response, especially during immunotherapy treatment, may be weaker than previously imagined. The research shows how the specific cells in the lymph ...

Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research ...

Dr. Regina Barzilay’s world turned upside down when she was diagnosed with breast cancer in 2014. It seemed to come out of nowhere. She didn’t know anyone in her family who had BRCA genes — the genes ...

Montell Jordan confirmed his cancer has returned and spread to his lymph nodes nearly a year after prostate removal surgery. Montell Jordan delivered a sobering health update during an appearance on ...

Papillary thyroid cancer (PTC) generally has a good prognosis, with 5-year relative survival rates of 99% for regional cancer that has spread to the lymph nodes. PTC is the most common type of thyroid ...

The demographics of lung cancer change every day. The disease, which directly affects the respiratory system, has long been associated with smokers — but that is rapidly changing. “Before it was rare, ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Next month, 108 colleagues from Bristol Myers Squibb will embark on a taxing journey from Cannon Beach, Ore. to Long Branch, N.J. as part of the 2025 Coast 2 Coast 4 Cancer (C2C4C) ride — nearly a ...

Aug 25 (Reuters) - Royalty Pharma (RPRX.O), opens new tab has agreed to buy a royalty interest in Amgen's (AMGN.O), opens new tab drug for small cell lung cancer from BeOne Medicines (688235.SS), ...

Please provide your email address to receive an email when new articles are posted on . The number of lung cancer cases was greater in the highest vs. lowest group of energy-adjusted ultra-processed ...

The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.